drugset / Trial / NCT01366352

Pharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets

NCT01366352

Phase 1 Completed 24 enrolled Bausch Health Americas, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

This was a single-center, double-blind, randomized, cross-over Phase 1 study in normal, healthy volunteers. Study treatment entailed single doses of two different formulations of MNTX tablets.

Timeline

Start
2004-02
Primary completion
2004-03
Completion
2004-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylnaltrexone Other / unclassified

Indications

No indication recorded.